Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Share-based Compensation (2023 - 2025)

Zenas BioPharma has reported Share-based Compensation over the past 3 years, most recently at $7.6 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $7.6 million for Q4 2025, up 37.94% from a year ago — trailing twelve months through Dec 2025 was $26.3 million (up 143.48% YoY), and the annual figure for FY2025 was $26.3 million, up 143.48%.
  • Share-based Compensation for Q4 2025 was $7.6 million at Zenas BioPharma, up from $7.3 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ZBIO hit a ceiling of $7.6 million in Q4 2025 and a floor of $947000.0 in Q1 2024.
  • Median Share-based Compensation over the past 3 years was $4.1 million (2024), compared with a mean of $3.9 million.
  • Peak annual rise in Share-based Compensation hit 468.74% in 2025, while the deepest fall reached 37.94% in 2025.
  • Zenas BioPharma's Share-based Compensation stood at $1.1 million in 2023, then surged by 384.14% to $5.5 million in 2024, then skyrocketed by 37.94% to $7.6 million in 2025.
  • The last three reported values for Share-based Compensation were $7.6 million (Q4 2025), $7.3 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.